Trump administration launches hemp pilot for some Medicare patients

Medicare is now being used as a federal test case for hemp-derived products, but only inside tightly controlled value-based care models and only for patients who meet narrow eligibility rules. The Centers for Medicare & Medicaid Services announced on April 1, 2026, the Substance Access Beneficiary Engagement Incentive, a voluntary program that lets participating organizations consult with eligible beneficiaries about hemp-derived products that may help improve symptom control. The agency said the pilot is meant to see whether the products can improve quality of life and lower spending, not to create a broad new Medicare benefit.

The incentive is capped at up to $500 a year per eligible beneficiary, and Medicare does not pay for the products. Beneficiaries are not supposed to file a Medicare claim for them. The pilot is available only in three Innovation Center models: ACO REACH, the Enhancing Oncology Model, and the Long-Term Enhanced ACO Design Model. LEAD participants cannot begin offering the incentive until January 1, 2027. For the current performance period, CMS said five accountable care organizations in ACO REACH had already submitted implementation plans for review, with initial approved participants expected to start on April 1, 2026.

Eligibility is limited. Beneficiaries generally must be at least 18, must not be pregnant or breastfeeding, must not meet a frailty exclusion, and must not have disqualifying conditions under the model. A physician must decide the hemp use is appropriate and document shared decision-making, including review of current medications, possible interactions and follow-up planning. Participating organizations also must submit and maintain an implementation plan that spells out the product, dosing, distribution frequency, beneficiary criteria and safeguards. CMS said it can reject or suspend participation because of the plan, compliance history or other program-integrity concerns, and it will collect quarterly reports from participants.

The program sits inside a broader Trump administration push to lower health costs and encourage research and innovation around hemp-derived products. CMS Administrator Dr. Mehmet Oz and CMS Innovation Center Director Abe Sutton framed the effort as a clinically supervised way to test new care tools in real-world settings, while CMS said it would not make therapeutic claims about hemp products outside the pilot itself.

Senior care advocates have greeted the move with guarded optimism. Ginny Helms, president and chief executive of LeadingAge Georgia, called the initiative a “potential game changer” for older adults dealing with chronic pain, sleep disturbances, anxiety and dementia-related agitation, and said better dosing could reduce polypharmacy, including antipsychotic and opioid use. LeadingAge’s Nicole Fallon also warned that state bans in places such as Idaho and Kansas could keep some accountable care organizations from participating at all. For CMS, the real test is whether this model produces measurable relief and savings before federal enthusiasm runs ahead of the science.